BR112022021228A2 - Derivado da 1,5-di-hidro-2,4-benzodiazepin-3-ona e aplicação do mesmo - Google Patents
Derivado da 1,5-di-hidro-2,4-benzodiazepin-3-ona e aplicação do mesmoInfo
- Publication number
- BR112022021228A2 BR112022021228A2 BR112022021228A BR112022021228A BR112022021228A2 BR 112022021228 A2 BR112022021228 A2 BR 112022021228A2 BR 112022021228 A BR112022021228 A BR 112022021228A BR 112022021228 A BR112022021228 A BR 112022021228A BR 112022021228 A2 BR112022021228 A2 BR 112022021228A2
- Authority
- BR
- Brazil
- Prior art keywords
- derivative
- dihydro
- application
- pimavanserin
- benzodiazepin
- Prior art date
Links
- KQMBNFRGIJUXOT-UHFFFAOYSA-N 1,2,4,5-tetrahydro-2,4-benzodiazepin-3-one Chemical class C1NC(=O)NCC2=CC=CC=C21 KQMBNFRGIJUXOT-UHFFFAOYSA-N 0.000 title abstract 4
- RKEWSXXUOLRFBX-UHFFFAOYSA-N pimavanserin Chemical compound C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1 RKEWSXXUOLRFBX-UHFFFAOYSA-N 0.000 abstract 4
- 229960003300 pimavanserin Drugs 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 abstract 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 abstract 1
- 206010048610 Cardiotoxicity Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 abstract 1
- 101150104779 HTR2A gene Proteins 0.000 abstract 1
- 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 abstract 1
- 101150013372 Htr2c gene Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039897 Sedation Diseases 0.000 abstract 1
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 231100000259 cardiotoxicity Toxicity 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000036280 sedation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010330893 | 2020-04-26 | ||
| CN202110288141 | 2021-03-17 | ||
| PCT/CN2021/089660 WO2021218863A1 (zh) | 2020-04-26 | 2021-04-25 | 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022021228A2 true BR112022021228A2 (pt) | 2022-12-06 |
Family
ID=78374068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022021228A BR112022021228A2 (pt) | 2020-04-26 | 2021-04-25 | Derivado da 1,5-di-hidro-2,4-benzodiazepin-3-ona e aplicação do mesmo |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12559471B2 (https=) |
| EP (1) | EP4144725B1 (https=) |
| JP (1) | JP7693709B2 (https=) |
| KR (1) | KR102832951B1 (https=) |
| CN (1) | CN115667236B (https=) |
| AU (1) | AU2021262281B2 (https=) |
| BR (1) | BR112022021228A2 (https=) |
| CA (1) | CA3172692C (https=) |
| WO (1) | WO2021218863A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115605202B (zh) | 2020-03-26 | 2025-10-28 | 盐野义制药株式会社 | 具有血清素受体结合活性的芳香族杂环衍生物 |
| CN121039114A (zh) | 2023-04-21 | 2025-11-28 | 江苏恩华药业股份有限公司 | 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物枸橼酸盐的晶型、制备方法及其应用 |
| WO2025044768A1 (zh) * | 2023-08-29 | 2025-03-06 | 江苏恩华药业股份有限公司 | 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物的制备方法和其中间体及其制备方法 |
| CN120329280A (zh) * | 2024-01-17 | 2025-07-18 | 江苏恩华药业股份有限公司 | 取代的1,2,4-四氢-3h-苯并二氮䓬-3-酮衍生物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60161986A (ja) * | 1983-12-24 | 1985-08-23 | Nippon Soda Co Ltd | イミダゾ（１，５−ａ）ピリジン−３−オン誘導体及びその製造方法 |
| ES2197160T3 (es) * | 1992-12-21 | 2004-01-01 | Smithkline Beecham Corp | Antagonistas fibronogeno bicicliclos. |
| EP0960104B1 (en) * | 1996-04-17 | 2004-06-16 | Bristol-Myers Squibb Pharma Company | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors |
| UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
| GT199800109A (es) * | 1997-08-06 | 2000-01-13 | Derivados de n-sulfonilglicinalquiniloxifenetilamida microbicidas. | |
| JP2003503476A (ja) * | 1999-07-06 | 2003-01-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | 環化アミド誘導体 |
| SI1720836T1 (sl) * | 2004-02-25 | 2014-06-30 | Eli Lilly And Company | 6-substituirani 2,3,4,5-tetrahidro-1h-benzo (d)azepini kot agonisti 5-ht2c receptorja |
| KR101594898B1 (ko) | 2005-07-15 | 2016-02-18 | 알바니 몰레큘라 리써치, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
| US7473778B2 (en) * | 2005-12-24 | 2009-01-06 | Boehringer Ingelheim International Gmbh | 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one |
| US20100222326A1 (en) | 2007-04-27 | 2010-09-02 | Ucb Pharma, S.A. | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders |
| JP5502733B2 (ja) * | 2007-07-26 | 2014-05-28 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ２ａ及びｄ３受容体の二重のモジュレーター |
| US9309200B2 (en) * | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| EP3409658B9 (en) * | 2016-01-29 | 2024-07-17 | ONO Pharmaceutical Co., Ltd. | Tetrahydronaphthalene derivative |
-
2021
- 2021-04-25 JP JP2022563189A patent/JP7693709B2/ja active Active
- 2021-04-25 CA CA3172692A patent/CA3172692C/en active Active
- 2021-04-25 BR BR112022021228A patent/BR112022021228A2/pt unknown
- 2021-04-25 KR KR1020227040086A patent/KR102832951B1/ko active Active
- 2021-04-25 EP EP21796540.9A patent/EP4144725B1/en active Active
- 2021-04-25 WO PCT/CN2021/089660 patent/WO2021218863A1/zh not_active Ceased
- 2021-04-25 CN CN202180029971.7A patent/CN115667236B/zh active Active
- 2021-04-25 AU AU2021262281A patent/AU2021262281B2/en active Active
-
2022
- 2022-10-20 US US18/048,340 patent/US12559471B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7693709B2 (ja) | 2025-06-17 |
| JP2023522078A (ja) | 2023-05-26 |
| EP4144725B1 (en) | 2025-11-26 |
| KR102832951B1 (ko) | 2025-07-10 |
| AU2021262281A1 (en) | 2022-11-24 |
| US12559471B2 (en) | 2026-02-24 |
| EP4144725A1 (en) | 2023-03-08 |
| WO2021218863A1 (zh) | 2021-11-04 |
| CN115667236A (zh) | 2023-01-31 |
| CA3172692C (en) | 2024-05-14 |
| AU2021262281B2 (en) | 2024-11-28 |
| US20230132621A1 (en) | 2023-05-04 |
| CA3172692A1 (en) | 2021-11-04 |
| CN115667236B (zh) | 2024-04-26 |
| EP4144725C0 (en) | 2025-11-26 |
| KR20230004662A (ko) | 2023-01-06 |
| EP4144725A4 (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022021228A2 (pt) | Derivado da 1,5-di-hidro-2,4-benzodiazepin-3-ona e aplicação do mesmo | |
| CY1124828T1 (el) | Αλλοστερικοι διαμορφωτες των νικοτινικων υποδοχεων ακετυλχολινης | |
| MA49055A (fr) | Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf | |
| BR112021020520A2 (pt) | Inibidores da di-hidro-orotato desidrogenase | |
| EP2968335A4 (en) | SYNTHESIS AND COMPOSITION OF COMPOUNDS USED TO TARGET TUMOR FORMING OF CONJUGATED AMINO ACID COMPOUNDS | |
| EP3733659A4 (en) | AROMATIC VINYL OR AROMATIC ETHYL DERIVATIVE, MANUFACTURING PROCESS FOR IT, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATION | |
| CY1120258T1 (el) | Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος | |
| BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
| BR112014022000A2 (pt) | compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende | |
| BR112012028445A2 (pt) | compostos de heteroarila bicíclica como moduladores de gpr119 | |
| EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
| BRPI0415657A (pt) | derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c | |
| BR112016024936A2 (pt) | moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes | |
| CY1116452T1 (el) | Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης | |
| BR112022006242A2 (pt) | Compostos aromáticos de arilmetileno como bloqueadores de canal do agitador de potássio kv1,3 | |
| CY1124574T1 (el) | Προφαρμακο παραγωγου αμινοξεος | |
| CY1119646T1 (el) | Προφαρμακο αμινοξεος που περιεχει φθοριο | |
| BR112015022864A8 (pt) | composto, composição farmacêutica e uso dos mesmos | |
| PA8603001A1 (es) | Compuestos utiles para el tratamiento de enfermedades | |
| MX2017001603A (es) | Derivados de piperazina como moduladores de los receptores x del higado. | |
| JOP20200272A1 (ar) | مُعدّلات تفارغية سبيروبيريدين لمستقبلات أستيل كولين نيكوتينية | |
| TN2015000240A1 (fr) | Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments | |
| BR112023015425A2 (pt) | Derivados de uracila como inibidores de trpa1 | |
| BR112015004511A8 (pt) | Derivados de pirazol carboxamida como moduladores de taar para uso no tratamento de diversas desordens, tais como depressão, diabetes e doença de parkinson | |
| BR112022007238A2 (pt) | Compostos modificadores derivados de anel de quatro membros, métodos para preparar os referidos compostos, composição e uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |